Source: New York Times

Lawyers involved in the multi-district litigation against Johnson & Johnson and Bayer's Xarelto argue that the "two major pharmaceutical companies, in an effort to protect their blockbuster drug, mislead editors at" the New England Journal of Medicine by leaving out laboratory data that could have showed the effect of a faulty blood testing device on the trial results. Bayer frequently declined to comment when asked about Xarelto trial results. Last "fall, Bayer submitted an analysis to the Europeanen Medicines Agency that was nearly identical to the approach used by the Duke researchers, comparing the outcomes of patients who had specific medical conditions with outcomes of those who did not."